Yahoo Finance

VIVEX Biologics Announces Presentation of Clinical Results of VIA Disc® During Webinar Series Hosted by The American Society of Pain & Neuroscience (ASPN)

Douglas Beall, M.D., chief of radiology services at Clinical Radiology of Oklahoma and principal investigator of the VAST study, will be presenting data from VIVEX’s 12-month study of VIA Disc® for ...
Yahoo Finance

VIVEX Biologics Announces Presentation of Clinical Results of VIA Disc® at The Orthobiologic Institute (TOBI) Virtual Symposium

“For patients currently suffering from degenerative disc disease, the availability of therapeutic options is limited or sub-optimal,” said Dr. Davis. “I believe intradiscal allogeneic treatments like ...
Medical Xpress

Minimally invasive disc injection reduces pain and improves function in chronic back pain, feasibility study finds

Patients received a single injection of 100 mg of VIA Disc NP, a micronized cadaveric disc tissue product reconstituted with saline. Under fluoroscopic guidance, the product was delivered into ...
Business Insider

Vivex Biologics Publishes New Medicare Real-World Evidence Study Showing VIA Disc® NP Significantly Reduces Opioid Use, Imaging, and Conservative Care Utilization in Patients ...

MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced the publication of a new real-world evidence study demonstrating ...
UPI

Cell injections could provide lasting relief of low back pain

An injection that relieves low back pain by helping damaged spinal discs regenerate appears to have sustained benefits, new clinical trial data show. Most patients who received an injection of VIA ...
Business Insider

VIVEX Biologics Publishes Initial Clinical Results of VIA Disc in The International Journal of Spine Surgery

First-ever published 12-month results from Level 1 intradiscal study for treating patients with one or two level symptomatic degenerative disc disease Early evidence suggests greater than 70% ...
manilatimes

Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration

MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND ...
manilatimes

Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in ...

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND ...